Baseline Characteristics and Survival of Adult Severe Sepsis Patients Treated With Drotrecogin Alfa (Activated) in a Global, Single-Arm, Open-Label Trial (ENHANCE

Arthur P. Wheeler; Christopher Doig; Theressa J. Wright; Kar Wong; Jean Louis Vincent; Gordon R. Bernard

doi:10.1378/chest.124.4_meetingabstracts.91s-c

Back

Shared by

Jean Louis Vincent

Université Libre de Bruxelles

Baseline Characteristics and Survival of Adult Severe Sepsis Patients Treated With Drotrecogin Alfa (Activated) in a Global, Single-Arm, Open-Label Trial (ENHANCE

Article 2003 en

Authors

AW
Arthur P. Wheeler
CD
Christopher Doig
TW
Theressa J. Wright

Related publications

Article2004

The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

Jean Louis Vincent, Gordon R. Bernard, Jean François Dhainaut, Mitchell M. Levy, Arthur P. Wheeler, William L. Macias

Article2004

The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

Rupert Beale, Jean Louis Vincent, Christopher J. Doig, Jean François Dhainaut, David P. Sundin, Theressa J. Wright

Article2003

Safety of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis: Comparison of Global ENHANCE to PROWES

Richard Beale, Theressa J. Wright, Kar Wong, Jean Louis Vincent, Gordon R. Bernard

Article2005

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Jean Louis Vincent, Gordon R. Bernard, Richard Beale, Christopher J. Doig, Christian Putensen, Jean-François Dhainaut, Antonio Artigas, Roberto Fumagalli, William L. Macias, Theressa J. Wright, Kar Wong, David P. Sundin, Mary Ann Turlo, Jonathan Janes

Article2003

Global ENHANCE Results Indicate Organ Function Improvement With Drotrecogin Alfa (activated) in Severe Sepsis Patient

Jean Louis Vincent, Bruce Light, Theressa J. Wright, Kar Wong, Gerald D. Johnson, Gordon R. Bernard

Baseline Characteristics and Survival of Adult Severe Sepsis Patients Treated With Drotrecogin Alfa (Activated) in a Global, Single-Arm, Open-Label Trial (ENHANCE

Discussion(0)

Related publications

The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

Safety of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis: Comparison of Global ENHANCE to PROWES

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Global ENHANCE Results Indicate Organ Function Improvement With Drotrecogin Alfa (activated) in Severe Sepsis Patient